TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20205741

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise (twice weekly for 12 weeks)
Number of subjects: 15
Study: 20205824

Group type: EXPERIMENTAL
Intervention: Pay-for-performance (P4P) condition
Number of subjects: 29

Group type: COMPARATOR
Intervention: Implementation as usual (IAU) condition
Number of subjects: 29
Study: 20205864

Group type: EXPERIMENTAL
Intervention: Weekly short-time recalls for EBF at week 6
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recall since-birth for EBF at week 6
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Weekly short-time recalls for PBF at week 6
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recall since-birth for PBF at week 6
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Weekly short-time recalls for EBF at week 12
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recall since-birth for EBF at week 12
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Weekly short-time recalls for PBF at week 12
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recall since-birth for PBF at week 12
Number of subjects: 30
Study: 20206456

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 3267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3267
Study: 20206940

Group type: EXPERIMENTAL
Intervention: Intravenous ECG monitoring during PICC insertion
Number of subjects: 6
Study: 20207638

Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (SNS)
Number of subjects: 62
Study: 20208057

Group type: EXPERIMENTAL
Intervention: Low-dose chloroquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 20210522

Group type: COMPARATOR
Intervention: Basal Cell Carcinomas (BCC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Squamous Cell Carcinomas (SCC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Premalignant Actinic Keratoses (AK)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Healthy Controls
Number of subjects: 28
Study: 20210645

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV) prime at week 0 followed by a 23-valent pneumococcal polysaccharide vaccine (PPV) boost at week 4
Number of subjects: 0

Group type: COMPARATOR
Intervention: PPV alone
Number of subjects: 0
Study: 20211302

Group type: EXPERIMENTAL
Intervention: Any beta-blocker for patients with LVSD
Number of subjects: 20441

Group type: EXPERIMENTAL
Intervention: Evidence-based beta-blocker for patients with LVSD
Number of subjects: 20441

Group type: EXPERIMENTAL
Intervention: Warfarin for patients with atrial fibrillation
Number of subjects: 20441

Group type: EXPERIMENTAL
Intervention: Aldosterone antagonist for patients with LVSD
Number of subjects: 20441

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator for patients with ejection fraction ≤35%
Number of subjects: 20441

Group type: EXPERIMENTAL
Intervention: Referral to disease management
Number of subjects: 20441
Study: 20211560

Group type: EXPERIMENTAL
Intervention: Oral masitinib at 7.5mg/kg/d
Number of subjects: 30
Study: 20211892

Group type: EXPERIMENTAL
Intervention: Doripenem
Number of subjects: 1830

Group type: COMPARATOR
Intervention: Comparators
Number of subjects: 1830
Study: 20212194

Group type: EXPERIMENTAL
Intervention: Intravitreous dexamethasone
Number of subjects: 0
Study: 20214479

Group type: EXPERIMENTAL
Intervention: Primary vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Revaccination
Number of subjects: 0
Study: 20214527

Group type: EXPERIMENTAL
Intervention: Lapatinib monotherapy
Number of subjects: 33
Study: 20214665

Group type: EXPERIMENTAL
Intervention: Mannitol challenge
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Exercise test
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Chlorine exposure
Number of subjects: 61
Study: 20214798

Group type: EXPERIMENTAL
Intervention: Additional parenteral nutrition (APN)
Number of subjects: 32
Study: 20215446

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 137
Study: 20215456

Group type: EXPERIMENTAL
Intervention: Intensive glycemia treatment
Number of subjects: 10251

Group type: COMPARATOR
Intervention: Standard glycemia treatment
Number of subjects: 10251
Study: 20215923

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) treatment
Number of subjects: 281
Study: 20215935

Group type: EXPERIMENTAL
Intervention: Combination therapy (COMB)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Placebo (PBO)
Number of subjects: 427
Study: 20216101

Group type: EXPERIMENTAL
Intervention: Food allergy screening (skin prick, atopy patch, serum-specific IgE, IgG, IgG4 testing)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Skin prick, atopy patch, and serum-specific testing
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristics curves for SIgG and SIgG4
Number of subjects: 22
Study: 20219110

Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine (PPV)
Number of subjects: 0
Study: 20219965

Group type: EXPERIMENTAL
Intervention: 1-year lifestyle intervention
Number of subjects: 663
Study: 20220059

Group type: EXPERIMENTAL
Intervention: (R)VAD+C regimen
Number of subjects: 113

Group type: COMPARATOR
Intervention: MIPI score
Number of subjects: 113

Group type: COMPARATOR
Intervention: Ki67
Number of subjects: 113

Group type: COMPARATOR
Intervention: Prognostic scoring system
Number of subjects: 113
Study: 20220062

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) before treatment (day 0) and on day 7 after induction chemotherapy
Number of subjects: 80
Study: 20221623

Group type: COMPARATOR
Intervention: Photodynamic therapy with verteporfin alone (PDT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy combined with intravitreal bevacizumab (COMB)
Number of subjects: 45
Study: 20222977

Group type: EXPERIMENTAL
Intervention: Canfosfamide plus pegylated liposomal doxorubicin (PLD) at 960/50 mg/m2
Number of subjects: 39
Study: 20223916

Group type: EXPERIMENTAL
Intervention: Caucasian ethnicity
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: European ancestry
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: West African ancestry
Number of subjects: 1010
Study: 20225395

Group type: EXPERIMENTAL
Intervention: Algorithm for identifying risk of myocardial ischaemia
Number of subjects: 305
Study: 20225992

Group type: EXPERIMENTAL
Intervention: Monthly intravenous C.E.R.A.
Number of subjects: 424
Study: 20226028

Group type: EXPERIMENTAL
Intervention: Heavy ion therapy (HIT) with a target dose of 60-66 Gy E, including 45 Gy PT and a carbon ion boost of 15-21 Gy E, administered weekly in fractions of 5-6 x 3 Gy E
Number of subjects: 0
Study: 20228610

Group type: EXPERIMENTAL
Intervention: CIMT measurements in FH patients
Number of subjects: 1624

Group type: EXPERIMENTAL
Intervention: CIMT measurements in MD patients
Number of subjects: 1624

Group type: COMPARATOR
Intervention: Body mass index and waist circumference in FH patients
Number of subjects: 1624

Group type: COMPARATOR
Intervention: Waist circumference in MD patients
Number of subjects: 1624

Group type: COMPARATOR
Intervention: Segment-specific completeness in FH patients
Number of subjects: 1624

Group type: COMPARATOR
Intervention: Segment-specific completeness in MD patients
Number of subjects: 1624
Study: 20230209

Group type: EXPERIMENTAL
Intervention: IV esomeprazole 40 mg twice daily for 48 hours (can continue for another 24 hours if no prepyloric enteral feedings planned)
Number of subjects: 44
Study: 20230418

Group type: EXPERIMENTAL
Intervention: Outpatient treatment of acute pulmonary embolism with low NT-proBNP levels (< 500 pg mL(-1)).
Number of subjects: 152
Study: 20230622

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 1250
Study: 20230905

Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy
Number of subjects: 105
Study: 20231152

Group type: EXPERIMENTAL
Intervention: Automatic capture management (CM)
Number of subjects: 160
Study: 20231202

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PRO) - TJ global score on a 100-mm VAS
Number of subjects: 66

Group type: COMPARATOR
Intervention: Physical examination measures (TJ swelling, TJ tenderness)
Number of subjects: 66
Study: 20231206

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: No immunosuppressive therapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SLE patients
Number of subjects: 42
Study: 20231595

Group type: EXPERIMENTAL
Intervention: Desired position of the eyebrows in women
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Desired position of the eyebrows in men
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Brow peak position
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Range of movement of the eyebrows
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aesthetic position of the medial and central brow
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Brow peak position recommendation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Surgical planning recommendation
Number of subjects: 40
Study: 20231626

Group type: EXPERIMENTAL
Intervention: Mobilization of circulating angiogenic cells (CACs)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Burn wound perfusion and vascularization
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: CAC levels in peripheral blood
Number of subjects: 31
Study: 20233136

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow cells (BMSC)
Number of subjects: 32
Study: 20233403

Group type: EXPERIMENTAL
Intervention: Risk factors associated with Road Traffic Injuries (RTI) in a driving population
Number of subjects: 1540
Study: 20233444

Group type: EXPERIMENTAL
Intervention: OncoCarta panel
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: ColoCarta panel
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Mutation profiling of metastatic lymph nodes
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Mutation frequencies
Number of subjects: 239
Study: 20233448

Group type: EXPERIMENTAL
Intervention: Value-based marketing intervention
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual-care marketing
Number of subjects: 360
Study: 20233976

Group type: EXPERIMENTAL
Intervention: MMSE score <26
Number of subjects: 2510

Group type: EXPERIMENTAL
Intervention: TTR <65%
Number of subjects: 2510

Group type: EXPERIMENTAL
Intervention: MMSE score <24
Number of subjects: 2510

Group type: EXPERIMENTAL
Intervention: MMSE score 24 to 25
Number of subjects: 2510

Group type: EXPERIMENTAL
Intervention: Improved anticoagulation
Number of subjects: 2510
Study: 20234331

Group type: EXPERIMENTAL
Intervention: PCV-7 vaccine administered at 2, 4, and 6 months after birth
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: PCV-7 vaccine administered
Number of subjects: 369
Study: 20236340

Group type: EXPERIMENTAL
Intervention: Menstrual migraine treatment episodes
Number of subjects: 153

Group type: COMPARATOR
Intervention: Nonmenstrual migraine treatment episodes
Number of subjects: 153
Study: 20236500

Group type: EXPERIMENTAL
Intervention: Argon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Xenon
Number of subjects: 0
Study: 20236700

Group type: EXPERIMENTAL
Intervention: LCZ696 100 mg
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: LCZ696 200 mg
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: LCZ696 400 mg
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Valsartan 80 mg
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Valsartan 320 mg
Number of subjects: 1328

Group type: COMPARATOR
Intervention: AHU377 200 mg
Number of subjects: 1328
Study: 20237039

Group type: EXPERIMENTAL
Intervention: PET-assisted management (group 1)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Standard care (group 2)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: PET-assisted management (group 3)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Ottawa-FIVE patients
Number of subjects: 111
Study: 20237066

Group type: EXPERIMENTAL
Intervention: Vitamin K concentration in subcutaneous adipose tissue
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Vitamin K concentration in visceral adipose tissue
Number of subjects: 459

Group type: COMPARATOR
Intervention: Plasma K(1) levels in women
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Circulating concentrations of uncarboxylated prothrombin in men
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Circulating concentrations of uncarboxylated prothrombin in women
Number of subjects: 459

Group type: COMPARATOR
Intervention: Percentage of undercarboxylated osteocalcin
Number of subjects: 459
Study: 20298558

Group type: EXPERIMENTAL
Intervention: Central arterial pressure and pulse wave velocity measurement
Number of subjects: 110
Study: 20298563

Group type: EXPERIMENTAL
Intervention: Patient activation intervention (letter to discuss thiazide diuretics)
Number of subjects: 54
Study: 20298564

Group type: EXPERIMENTAL
Intervention: Patient activation strategy (letters and incentives to discuss thiazides)
Number of subjects: 21
Study: 20298923

Group type: EXPERIMENTAL
Intervention: DES overlap
Number of subjects: 1012
Study: 20298926

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study: 20299029

Group type: EXPERIMENTAL
Intervention: Subcoronary Ross procedure
Number of subjects: 501
Study: 20299511

Group type: EXPERIMENTAL
Intervention: Velaglucerase alfa (60 U/kg per infusion) during phase 1/2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Velaglucerase alfa (30 U/kg per infusion) during extension study
Number of subjects: 12
Study: 20299634

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) measurement
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Antibiotic pretreatment
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Procalcitonin serum levels
Number of subjects: 925
Study: 20299957

Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil in HIV-infected patients on efavirenz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil in HIV-infected patients on lopinavir/ritonavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil in HIV-infected patients on atazanavir/ritonavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil
Number of subjects: 0
Study: 20307284

Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid supplement (exact dosage not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fatty acid analysis of RBCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fatty acid analysis of WBCs
Number of subjects: 0
Study: 20307398

Group type: EXPERIMENTAL
Intervention: Controlled-release alpha lipoic acid (CRLA) 600 mg twice daily for 16 weeks
Number of subjects: 6
Study: 20331856

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 52

Group type: COMPARATOR
Intervention: No dobutamine
Number of subjects: 52
Study: 20334673

Group type: EXPERIMENTAL
Intervention: Liquid nicotine delivery system (Smoke-Break)
Number of subjects: 69
Study: 20334992

Group type: EXPERIMENTAL
Intervention: Medial compartment disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Axial compartment disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Superolateral compartment disease
Number of subjects: 0
Study: 20335221

Group type: EXPERIMENTAL
Intervention: Placenta growth factor (PlGF) levels in patients with SCD
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Erythroid expression of PlGF simulated in normal mice using a lentivirus vector
Number of subjects: 123
Study: 20335545

Group type: EXPERIMENTAL
Intervention: Spiced Burger (SB) seasoned with antioxidant spice blend
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control Burger (CB) not seasoned with spice blend
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Spiced Burger (SB)
Number of subjects: 11
Study: 20335583

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 20338042

Group type: EXPERIMENTAL
Intervention: Medial third of the tibial tuberosity as a reference for tibial rotational alignment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medial border of the tibial tubercle as a reference for tibial rotational alignment
Number of subjects: 80
Study: 20338746

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy followed by low intensity 'maintenance' chemotherapy (6-drug regimen with local therapy of surgery and/or radiotherapy followed by 9 courses of vincristine, actinomycin D and cyclophosphamide (VAC)) for SRG.
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: High dose monotherapy followed by low dose maintenance chemotherapy (VAC) for PRG.
Number of subjects: 146
Study: 20339536

Group type: EXPERIMENTAL
Intervention: 40 mg/day simvastatin for 6 weeks
Number of subjects: 3932

Group type: EXPERIMENTAL
Intervention: 40 mg/day pravastatin for 24 weeks
Number of subjects: 3932

Group type: EXPERIMENTAL
Intervention: 10 mg/day atorvastatin for 8 weeks
Number of subjects: 3932
Study: 20345222

Group type: EXPERIMENTAL
Intervention: (125)I-mAb 425 radioimmunotherapy (RIT)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: (125)I-mAb 425 and temozolomide (TMZ+RIT)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Historical control group (CTL)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 192

Group type: COMPARATOR
Intervention: RIT vs CTL
Number of subjects: 192

Group type: COMPARATOR
Intervention: TMZ+RIT vs CTL
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: TMZ+RIT vs RIT
Number of subjects: 192
Study: 20346127

Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol fixed combination (FC)
Number of subjects: 383
Study: 20346156

Group type: EXPERIMENTAL
Intervention: Living with Hope Program (LWHP)
Number of subjects: 200
Study: 20346568

Group type: EXPERIMENTAL
Intervention: Neutral head position (mean angle -1 degrees) in pre-school children
Number of subjects: 61

Group type: COMPARATOR
Intervention: Head-extension position (mean angle 13 degrees) in pre-school children
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Neutral head position (mean angle -0.4 degrees) in school children
Number of subjects: 61

Group type: COMPARATOR
Intervention: Head-extension position (mean angle 15.7 degrees) in school children
Number of subjects: 61
Study: 20346578

Group type: EXPERIMENTAL
Intervention: Focal laser ablation (FLA)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Postablation MRI
Number of subjects: 4
Study: 20347684

Group type: EXPERIMENTAL
Intervention: 1-hour free-living walking in a flat public park with GPS recording at 0.5 Hz
Number of subjects: 57
Study: 20348194

Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combined EBUS-TBNA and EUS-B-FNA
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combined EUS-B-FNA with EBUS-TBNA
Number of subjects: 150
Study: 20348198

Group type: EXPERIMENTAL
Intervention: Adherent group (met new LCD criteria)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Nonadherent group (failed to meet new LCD criteria)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Patients who did not receive any special adherence intervention
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall adherence
Number of subjects: 150
Study: 20350136

Group type: EXPERIMENTAL
Intervention: Intermediate CYP2D6 metabolism (0.5 SGD)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CYP2C19 poor metabolizers
Number of subjects: 100
Study: 20350189

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment during pregnancy (IPTp)
Number of subjects: 549
Study: 20350190

Group type: EXPERIMENTAL
Intervention: MVA
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MVA (1 x 10(7) TCID(50) intradermally)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MVA (1 x 10(7) TCID(50) intramuscularly)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MVA (intradermally)
Number of subjects: 36
Study: 20350192

Group type: EXPERIMENTAL
Intervention: Artemisinin derivatives treatment
Number of subjects: 0
Study: 20350302

Group type: EXPERIMENTAL
Intervention: LY450139 (100 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: LY450139 (140 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 20350831

Group type: EXPERIMENTAL
Intervention: OPA3A deficiency (as in optic atrophy type 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Green fluorescent protein tagged OPA3 expression studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loss of OPA3A
Number of subjects: 0
Study: 20354183

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily
Number of subjects: 191
Study: 20354489

Group type: EXPERIMENTAL
Intervention: Cryoplasty technique using the PolarCath device
Number of subjects: 100
Study: 20354809

Group type: EXPERIMENTAL
Intervention: Chronic InterStim Therapy device (Medtronic) implantation
Number of subjects: 120
Study: 20357040

Group type: EXPERIMENTAL
Intervention: Serum linoleic acid (LA, 18:2n-6)
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Serum arachidonic acid (AA, 20:4n-6)
Number of subjects: 1098
Study: 20357194

Group type: EXPERIMENTAL
Intervention: Spectral-domain optical coherence tomography (SD-OCT) and confocal scanning laser ophthalmoscopy (cSLO)
Number of subjects: 26
Study: 20359362

Group type: EXPERIMENTAL
Intervention: Commercial venue group
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Public venue group
Number of subjects: 321

Group type: COMPARATOR
Intervention: Private venue group
Number of subjects: 321
Study: 20361905

Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination
Number of subjects: 5

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 5